Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / DTCFF - Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

DTCFF - Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

Defence Therapeutics Inc Cl A

2024-03-27 17:08:02 ET

Investing in healthcare

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology. The technology helps bio drugs overcome intracellular barriers, making them more effective. Defence is excited about three upcoming clinical trials, expected to start by the end of the year, which will be important for the company's growth. Defence is also actively working to license their technology to other companies. The mRNA therapeutics market is projected to reach close to $130 billion by 2030, making the potential for Defence's growth promising.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

?

Stock Information
Company Name: Defence Therapeutics Inc Cl A
Stock Symbol: DTCFF
Market: OTC
Website: defencetherapeutics.com
Menu
DTCFF DTCFF Quote DTCFF Short DTCFF News DTCFF Articles DTCFF Message Board
Get DTCFF Alerts

News, Short Squeeze, Breakout and More Instantly...